Chengdu Huashen Group

Chengdu Huashen Group is a prominent Chinese pharmaceutical enterprise focused on the modernization of Traditional Chinese Medicine (TCM) and the development of innovative biopharmaceuticals. The company's portfolio is anchored by Licartin, a first-in-class radioimmunotherapy for primary liver cancer, and Sanqi Tongshu Capsule, a widely used treatment for cardiovascular and cerebrovascular diseases. Headquartered in Chengdu, the group integrates research, development, manufacturing, and marketing to provide comprehensive healthcare solutions. It is publicly traded on the Shenzhen Stock Exchange and continues to expand its presence in oncology and chronic disease management. The company maintains a strong commitment to technological advancement, bridging the gap between traditional therapies and modern clinical needs.